Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Lijun Zhang et al.|The Lancet|2014Cited by 4.7k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Alan S. Coates, Binghe Xu, Andrew Tutt et al.|Annals of Oncology|2015Cited by 1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Harold J. Burstein et al.|Annals of Oncology|2017Cited by 1.3k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyW. Eiermann, Semiglazov Vf, Stefan Paepke et al.|Annals of Oncology|2001Cited by 714